Bank of New York Mellon
SGP

Bank of New York Mellon’s SpyGlass Pharma SGP Stock Holding History

Bank of New York Mellon’s Portfolio SGP Stock Details SGP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$533K Buy
+23,944
New +$519K ﹤0.01% 3721

Other funds holding SGP

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
SCV
Sands Capital Ventures Arlington, Virginia $614M AUM 19.92% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Bank of New York Mellon's SGP Position: Q2 2026 in Review

Bank of New York Mellon opened a new position in SpyGlass Pharma (SGP) in Q2 2026: 23,944 shares worth $533K. The stake represents ﹤0.01% of the portfolio and ranks #3721 among its holdings.

52 funds tracked by Wall St. Rank hold SGP as of Q2 2026.

  • Bank of New York Mellon held 23,944 shares of SpyGlass Pharma worth $533K as of Q2 2026.
  • SpyGlass Pharma was a new Bank of New York Mellon position in Q2 2026.
  • SpyGlass Pharma made up ﹤0.01% of Bank of New York Mellon's portfolio in Q2 2026, its #3721 holding.
  • 52 funds tracked by Wall St. Rank held SpyGlass Pharma as of Q2 2026.

Based on Bank of New York Mellon's 13F filing for Q2 2026, filed 6 Aug 2026.